AI brief of an SEC Form 8-K · Charles River Laboratories (CRL)

Charles River Q3 revenue falls 0.5% to $1.00 billion; non-GAAP EPS $2.43

Mixed Impact 3 of 5 earnings Written later

Charles River reported third-quarter 2025 revenue of $1.00 billion, down 0.5% from $1.01 billion a year earlier, and non-GAAP diluted EPS of $2.43, down 6.2% from $2.59. GAAP diluted EPS was $1.10, down from $1.33, mainly due to a $0.33 per share loss on venture capital and strategic investments. The company narrowed its 2025 outlook to the middle and upper ends of its prior revenue and EPS ranges, with non-GAAP EPS now estimated at $10.10 to $10.30.

Key points

  • Q3 revenue was $1.00 billion, down 0.5%; organic revenue fell 1.6%.
  • Non-GAAP diluted EPS was $2.43, down 6.2% from $2.59; GAAP diluted EPS was $1.10 versus $1.33.
  • 2025 non-GAAP EPS estimate is now $10.10 to $10.30, compared with $9.90 to $10.30 previously.
  • RMS segment revenue rose 7.9% to $213.5 million, while DSA revenue fell 2.3% to $600.7 million.

The filing

CompanyCharles River Laboratories (CRL)
Form8-K, current report
Filed with the SECNov 5, 2025, 7:16 AM ET
Accession number0001100682-25-000041

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:11 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.